Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A, Siegel RL. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233–54. https://doi.org/10.3322/CAAC.21772.

Article  PubMed  Google Scholar 

Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10–32. https://doi.org/10.1016/J.ANNONC.2022.10.003.

Article  PubMed  Google Scholar 

Colon cancer—guidelines. Detail Available online: https://www.nccn.org/guidelines/guidelines-detail?id=1428. Accessed on 22 May 2025.

Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29:1108–19. https://doi.org/10.1093/ANNONC/MDY100.

Article  PubMed  PubMed Central  Google Scholar 

Tan RYC, Camat MD, Ng M, Lim TH, Lim AST, Lim KH, et al. HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients. Ann Oncol. 2018;29:1598–603. https://doi.org/10.1093/ANNONC/MDY156.

Article  PubMed  Google Scholar 

Tosi F, Sartore-Bianchi A, Lonardi S, Amatu A, Leone F, Ghezzi S, et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin Colorectal Cancer. 2020;19:256-262.e2. https://doi.org/10.1016/J.CLCC.2020.06.009.

Article  PubMed  Google Scholar 

Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, et al. Her2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist. 2019;24:1395–402. https://doi.org/10.1634/THEONCOLOGIST.2018-0785.

Article  PubMed  PubMed Central  Google Scholar 

Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54. https://doi.org/10.1038/NRC1609.

Article  PubMed  Google Scholar 

Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238:562–70. https://doi.org/10.1002/PATH.4679.

Article  PubMed  PubMed Central  Google Scholar 

Bartley K, Snider J, Cho-Phan C, Wang J, Martin P, Simon C, et al. The prognostic impact of human epidermal growth factor receptor 2 status in metastatic colorectal cancer. Future Sci OA. 2025. https://doi.org/10.1080/20565623.2025.2527482.

Article  PubMed  PubMed Central  Google Scholar 

Yagisawa M, Sawada K, Nakamura Y, Fujii S, Yuki S, Komatsu Y, et al. Prognostic value and molecular landscape of HER2 low-expressing metastatic colorectal cancer. Clin Colorectal Cancer. 2021;20:113-120.e1. https://doi.org/10.1016/J.CLCC.2020.11.002.

Article  PubMed  Google Scholar 

Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, et al. Impact of human epidermal growth factor receptor 2 in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab or anti-EGFRs: exploratory analysis of eight randomized trials. J Clin Oncol. 2025. https://doi.org/10.1200/JCO-25-01003.

Article  PubMed  Google Scholar 

Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, et al. HER2 gene expression levels are predictive and prognostic in patients with metastatic colorectal cancer enrolled in CALGB/SWOG 80405. J Clin Oncol. 2024;42:1890–902. https://doi.org/10.1200/JCO.23.01507.

Article  PubMed  Google Scholar 

Sartore-Bianchi A, Marsoni S, Amatu A, Torri V, Bonoldi E, Bardelli A, et al. How to test HER2 for predicting resistance to anti-epidermal growth factor receptor therapy in metastatic colorectal cancer? evidence from the secondary analysis of biomarkers of CALGB/SWOG 80405. J Clin Oncol. 2024;42:3631–2. https://doi.org/10.1200/JCO.24.00805/ASSET/79D4B87C-2CC3-482A-B255-ED179587814E/ASSETS/JCO.24.00805.FP.PNG.

Article  PubMed  Google Scholar 

Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–7. https://doi.org/10.1038/nature14969.

Article  PubMed  PubMed Central  Google Scholar 

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3:99ra86. https://doi.org/10.1126/SCITRANSLMED.3002442.

Article  PubMed  PubMed Central  Google Scholar 

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508–23. https://doi.org/10.1158/2159-8290.CD-11-0109.

Article  PubMed  Google Scholar 

Raghav K, Loree JM, Morris JS, Overman MJ, Yu R, Meric-Bernstam F, et al. Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol. 2019;3:1–13. https://doi.org/10.1200/PO.18.00226.

Article  PubMed  Google Scholar 

Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study. Ann Oncol. 2017;28:3009–14. https://doi.org/10.1093/ANNONC/MDX546.

Article  PubMed  Google Scholar 

Ciardiello D, Bielo LB, Napolitano S, Latiano TP, De Stefano A, Tamburini E, et al. Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial. ESMO Open. 2025. https://doi.org/10.1016/j.esmoop.2025.104511.

Article  PubMed  PubMed Central  Google Scholar 

Germani MM, et al. The prognostic and predictive role of HER2 amplification/overexpression and HER2 mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials. J Clin Oncol. 2025;43:3537.

Raghav KPS, Guthrie KA, Tan B, Denlinger CS, Fakih M, Overman MJ, et al. Trastuzumab plus pertuzumab versus cetuximab plus irinotecan in patients with RAS/BRAF wild-type, HER2-positive, metastatic colorectal cancer (S1613): a randomized phase II trial. J Clin Oncol. 2025. https://doi.org/10.1200/JCO-24-01710/SUPPL_FILE/PROTOCOL_JCO-24-01710.PDF.

Article  PubMed  Google Scholar 

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46. https://doi.org/10.1016/S1470-2045(16)00150-9.

Article  PubMed  Google Scholar 

Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28:1481–91. https://doi.org/10.1038/MODPATHOL.2015.98.

Article  PubMed  Google Scholar 

Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, et al. Prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17:198–205. https://doi.org/10.1016/J.CLCC.2018.05.006.

Article  PubMed  Google Scholar 

Lee WS, Park YH, Lee JN, Baek JH, Lee TH, Ha SY. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med. 2014;3:674. https://doi.org/10.1002/CAM4.228.

Article  PubMed  PubMed Central  Google Scholar 

Shan L, Lv Y, Bai B, Huang X, Zhu H. Variability in HER2 expression between primary colorectal cancer and corresponding metastases. J Cancer Res Clin Oncol. 2018;144:2275–81. https://doi.org/10.1007/S00432-018-2744-Z.

Article  PubMed  PubMed Central  Google Scholar 

DiPeri TP, Kong K, Varadarajan K, Karp DD, Ajani JA, Pant S, et al. Discordance of HER2 expression and/or amplification on repeat testing. Mol Cancer Ther. 2023;22:976–84. https://doi.org/10.1158/1535-7163.MCT-22-0630/727379/AM/DISCORDANCE-OF-HER2-EXPRESSION-AND-OR.

Article  PubMed  PubMed Central  Google Scholar 

D’Angelo F, Monnien F, Overs A, Pem I, Dor F, Abad M, et al. Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer. Diagn Pathol. 2024;19:88. https://doi.org/10.1186/S13000-024-01508-Y.

Article  PubMed